Adaptin Bio is a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues.
Charlotte, NC
Joined April 2025
- Tweets124
- Following60
- Followers16
- Likes3
A cancer diagnosis is one part of clinical trial eligibility. Some studies also look for a specific tumor marker. Adaptin’s published APTN-101 study design specifies EGFRvIII-expressing glioblastoma.
Read about the study: bit.ly/4gmpBQ2
$APTN
9
“Immunotherapy” describes a category of treatments. Some release brakes on immune activity. Others use immune cells as the treatment.
Understanding the approach helps put a research headline in context.
Explore the science: adaptinbio.com $APTN
3
A recent UCLA-led glioblastoma study linked higher T-cell density inside tumors with longer survival following dual checkpoint immunotherapy. A finding to investigate further, not evidence about APTN-101.
Read the research: bit.ly/4zB2nhm $APTN
14
This #HealthLiteracyMonth, we covered:
🧬 Tumor heterogeneity
🧠 Why surgery can't reach every cell
🚧 The blood-brain barrier
🚏 How BRiTE is designed to carry therapies
📖 Phase 1, decoded
🔗 How APTN-101 is designed to connect cells
Thanks for learning with us.
5
One end binds a marker on glioblastoma cells. The other binds T cells.
That's the idea behind APTN-101, Adaptin Bio's investigational bispecific T-cell engager: one molecule designed to connect an immune cell to a tumor cell.
13
You'll see "investigational" in a lot of biotech posts, including ours.
It means a therapy is being studied in clinical research and is not yet approved by regulators.
We're decoding the terms behind early clinical research. $APTN
6
Some therapies can't get into the brain on their own. So what if they caught a ride?
Adaptin Bio's investigational BRiTE platform is designed to use activated T cells to carry T-cell engagers across the blood-brain barrier.
$APTN
1
3
More than 95% of small-molecule drugs and more than 99% of large-molecule drugs do not cross the blood-brain barrier.
That delivery challenge is one of the questions shaping Adaptin Bio's investigational research.
#HealthLiteracyMonth $APTN
1
5
One tumor can contain cells with different target markers. That’s one aspect of tumor heterogeneity and a challenge shaping Adaptin’s research.
For #HealthLiteracyMonth, we’re explaining the science behind the strategy.
$APTN
1
5
Reaching the brain. Addressing differences among tumor cells.
Adaptin Bio President CEO Michael Roberts outlined how these two challenges shape Adaptin’s research into T-cell based delivery and modular tumor targeting.
$APTN
1
12